Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Colorectal Neoplasms 44Squamous Cell Carcinoma of Head and Neck 22Head and Neck Neoplasms 21Rectal Neoplasms 17Colonic Neoplasms 15Neoplasm Metastasis 13Neoplasms 12Carcinoma, Squamous Cell 10Carcinoma, Non-Small-Cell Lung 10Recurrence 5Pancreatic Neoplasms 5Esophageal Neoplasms 4Mouth Neoplasms 3Lung Neoplasms 3Laryngeal Neoplasms 3Laryngeal Diseases 3Breast Neoplasms 3Tongue Neoplasms 2Stomach Neoplasms 2Sarcoma 2Pharyngeal Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Neoplasms, Squamous Cell 2Hereditary Sensory and Autonomic Neuropathies 2Glioma 2Glioblastoma 2Colorectal Cancer Metastatic 2Adenocarcinoma of Lung 2Adenocarcinoma Of Esophagus 2

Interventions

Temozolomide 52Radiotherapy 24Bevacizumab 23Radiation 10Magnetic Resonance Spectroscopy 7Lomustine 7Carmustine 7Radiosurgery 6Surgical Procedures, Operative 5Irinotecan 5Radiotherapy, Intensity-Modulated 4Nivolumab 4Ipilimumab 4Erlotinib Hydrochloride 4Cilengitide 4Aminolevulinic Acid 4vocimagene amiretrorepvec 3vitespin 3sargramostim 3poly ICLC 3pembrolizumab 3fluoromisonidazole 3carmustine, poliferprosan 20 drug combination 3Vorinostat 3TPI-287 3O(6)-benzylguanine 3Granulocyte-Macrophage Colony-Stimulating Factor 3Flucytosine 3Dynamic Contrast Enhanced Magnetic Resonance Imaging 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Glioblastoma × Cetuximab × Clear all
NCT01884740 2022-08-09

Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22

Weill Medical College of Cornell University

Phase 1/2 Terminated
13 enrolled 6 charts
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

NCT01044225 2012-03-22

Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma

Universitair Ziekenhuis Brussel

Phase 2 Terminated
12 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡